U.S. flag An official website of the United States government
  1. Home
  2. Drug Databases
  3. Drug Shortages

FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Report a Drug Shortage | Contact Us | FAQ | Background Info | Get Email Alerts | Download Current Drug Shortages

Start Over | Back to Previous Screen

Lutetium Lu 177 Vipivotide Tetraxetan (Pluvicto) Injection
Status: Currently in Shortage
»Date first posted: 03/07/2023
»Therapeutic Categories: Oncology

Advanced Accelerator Applications USA, Inc. (Reverified 05/11/2023)

Company Contact Information:

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan) injection, for intravenous use 27 mCi/mL; Colorless Type I glass 30 mL single-dose vial containing 7.4 GBq (200 mCi) ± 10% of lutetium Lu 177 vipivotide tetraxetan (NDC 69488-010-61) Availability: Limited; Contact Novartis at 1-844-367-3222 or customerserv-us.aaa@novartis.com There are challenges in meeting demand and no therapeutic equivalents are available. For more information, please see the attached:
Dear Healthcare Provider update April 21, 2023
Back to Top